Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Guihao Chen
Proteomic results indicate inhibition of complement cascades is one of the mechanisms underlying the protective effects of Tongxinluo against myocardial infarction
Abstract Objective: Tongxinluo (TXL), a traditional Chinese medicine, has demonstrated cardioprotective effects in acute myocardial infarction (AMI), yet its impact on myocardial protein profiles remains largely unexplored. This study aimed to elucidate the proteomic mechanisms underlying the therapeutic effects of TXL in AMI. Methods: AMI was induced via left anterior descending artery ligation in C57BL/6J mice. TXL was administered by oral gavage during the acute phase.
TPI1-loaded heart-homing polymeric nanoparticles alleviate acute myoca
Back to Journals » International Journal of Nanomedicine » Volume 20 Authors Pan Q , Chen G, Zhuang X, Li F, Yang Y Received 5 May 2025 Accepted for publication 29 July 2025 Published 27 August 2025 Volume 2025:20 Pages 10353—10367 DOI https://doi.org/10.2147/IJN.S533628 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Xing Zhang Qi Pan,1,* Guihao Chen,1,* Xiaoli Zhuang,2,* Fei Li,3 Yuejin Yang1 1State...
Traditional Chinese Medicine Compound and Clinical Outcomes in Acute Myocardial Infarction-Reply
Traditional Chinese Medicine Compound and Clinical Outcomes in Acute Myocardial Infarction—Reply Traditional Chinese Medicine Compound and Clinical Outcomes of Patients With Acute Myocardial Infarction Yuejin Yang, MD, PhD; Xiangdong Li, MD, PhD; Guihao Chen, MD, PhD; Ying Xian, MD, PhD; Haitao Zhang, MD, PhD; Yuan Wu, MD; Yanmin Yang, MD; Jianhua Wu, MD; Chuntong Wang, MD; Shenghu He, MD; Zhong Wang, MD; Yixin Wang, MD; Zhifang Wang, MD; Hui Liu, MD; Xiping Wang, MD; Minzhou Zhang, MD; Jun...
Triple Hybrid Cellular Nanovesicles Promote Cardiac Repair after Ischemic Reperfusion
Download Hi-Res ImageDownload to MS-PowerPointCite This:ACS Nano 2024, XXXX, XXX Terms & Conditions Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses).
Traditional Chinese Medicine for ST-Segment Elevation Myocardial Infarction
Traditional Chinese Medicine Compound and Clinical Outcomes of Patients With Acute Myocardial Infarction Yuejin Yang, MD, PhD; Xiangdong Li, MD, PhD; Guihao Chen, MD, PhD; Ying Xian, MD, PhD; Haitao Zhang, MD, PhD; Yuan Wu, MD; Yanmin Yang, MD; Jianhua Wu, MD; Chuntong Wang, MD; Shenghu He, MD; Zhong Wang, MD; Yixin Wang, MD; Zhifang Wang, MD; Hui Liu, MD; Xiping Wang, MD; Minzhou Zhang, MD; Jun Zhang, MD, PhD; Jia Li, MD; Tao An, MD; Hao Guan, MD; Lin Li, MD; Meixia Shang, MD; Chen Yao, MD;...
Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial | Complementary and Alternative Medicine | JAMA | JAMA Network
Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial Key Points Question Among patients with acute ST-segment elevation myocardial infarction (STEMI), does the addition of a traditional Chinese medicine compound (Tongxinluo) as an adjunctive treatment to guideline-directed therapies improve clinical outcomes?
Development of heart failure with preserved ejection fraction is independent of eosinophils in a preclinical model
1 INTRODUCTION With a rapid increase in its incidence and prevalence, heart failure (HF) is a major public health issue.1 Currently, HF with preserved left ventricular ejection fraction (HFpEF) has been recognized as the major form of HF, with a 5-year survival rate after the first hospitalization of 35%–40%.1 HFpEF is a systemic syndrome characterized by diastolic dysfunction, classic HF symptomatology (shortness of breath, edema, and exercise intolerance), and a normal left ventricular...
A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Coronary heart disease is the leading cause of death worldwide. The treatment of choice for reducing ischemic injury and limiting infarct size in patients with ST-segment elevated myocardial infarction is timely and effective myocardial reperfusion via primary percutaneous coronary intervention (PCI)1,2. However, reperfusion causes additional damage, which can account for up to 30 percent of the final infarct size3.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Guihao
Contact Guihao, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack